Effects of Erythropoietin Payment Policy on Cardiovascular Outcomes of Peritoneal Dialysis Patients: Observational Study

• Published in: JMIR medical informatics 2020-12, Vol.8 (12), p.e18716-e18716
• Main Authors: Hou, Ying-Hui, Yang, Feng-Jung, Lai, I-Chun, Lin, Shih-Pi, Wan, Thomas Th, Chang, Ray-E
• Format: Article
• Language: English
• Subjects: Anemia; Comorbidity; Data analysis; FDA approval; Fines & penalties; Kidney diseases; Medicare; Observational studies; Original Paper; Patients; Peritoneal dialysis; Prospective payment systems; Survival analysis
• ISSN: 2291-9694; 2291-9694
• DOI: 10.2196/18716

The change in the reimbursement policy of erythropoietin administration to patients receiving peritoneal dialysis by the Taiwan National Health Insurance (NHI) system provided a natural experimental venue to examine whether cardiovascular risk differs when maintaining the hematocrit (Hct) level below or above 30%. The aim of this study was to analyze the impact of loosening the erythropoietin payment criteria for peritoneal dialysis patients on their cardiovascular outcomes. Two cohorts of incident peritoneal dialysis patients were identified according to the time before and after relaxation of the NHI's erythropoietin payment criteria, designated cohort 1 (n=1759) and cohort 2 (n=2981), respectively. The cohorts were matched according to propensity scores (1754 patients in each cohort) and then followed up for cardiovascular events, which were analyzed with Cox regressions. For the composite cardiovascular endpoint, patients in cohort 2 had a significantly lower risk than those in cohort 1. However, subgroup analysis showed that this risk reduction was observed only in patients with diabetes. After loosening erythropoietin payment criteria, reduced cardiovascular risks were observed, particularly for patients with diabetes. These results indicate that it is crucial to maintain an Hct level above 30% to reduce the cardiovascular risk in patients with diabetes undergoing peritoneal dialysis.